Maria Chiara Cappelletto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Chiara Cappelletto has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Giacomo Corleone
Department of Surgery and Cancer, The Imperial Centre for Translational and Experimental Medicine, Imperial College London, London, UK
2 shared publications - Tiziana Bruno
Microbiology and Virology Unit, San Gallicano Dermatological Institute IRCCS
2 shared publications - Andrea Mengarelli
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
1 shared publication - Belinda Palermo
Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy
1 shared publication Bruno Amadio
Gene Expression and Cancer Models Unit, Department of Research and Advanced Technologies Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy
1 shared publication- Clelia Cortile
Gene Expression and Cancer Models Unit, Department of Research and Advanced Technologies Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Taylor & Francis in Epigenetics Reports
- Vol. 4 (1)
Epigenomic profiling of H3K27ac in a primary patient-derived multiple myeloma cell line using two different low-input methods with concordant results
Dysregulation of epigenetic and genetic mechanisms driving malignant transformation is a hallmark of cancer [1]. In multiple myeloma (MM), a plasma cell malignancy characterized by clonal expansion...
- 26 August 2026
- Published by Taylor & Francis in Epigenetics Reports
- Vol. 4 (1)
Open AccessEpigenomic profiling of H3K27ac in a primary patient-derived multiple myeloma cell line using two different low-input methods with concordant results
Dysregulation of epigenetic and genetic mechanisms driving malignant transformation is a hallmark of cancer [1]. In multiple myeloma (MM), a plasma cell malignancy characterized by clonal expansion...
- Open Access
- 11 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (24) , 2945-2962
Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy
Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.
- 11 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (24) , 2945-2962
Open AccessNuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy
Multiple myeloma (MM) continues to be an incurable malignancy, even with recent therapeutic advancements. Although epigenetic dysregulation at cis-regulatory elements is known to drive disease progression, the complete molecular mechanisms underlying these alterations are poorly understood. Using Assay for Transposase-Accessible Chromatin with high-throughput sequencing analysis combined with the computational footprinting of CD138+ cells from 55 patients with MM, we depicted the dynamic changes in chromatin accessibility during disease progression and identified nuclear respiratory factor 1 (NRF1) as a master regulator of vital MM survival pathways. We demonstrated that NRF1 maintains proteasome homeostasis by orchestrating the ubiquitination pathway, which is essential for MM cell survival. We discovered a novel enhancer element that physically interacts with the NRF1 promoter, sustaining its expression. Targeting this enhancer RNA reduced NRF1 levels and increased tumor cell sensitivity to bortezomib (BTZ), suggesting therapeutic potential. In xenograft models, we showed that antisense oligonucleotides targeting the NRF1 enhancer, either alone or combined with BTZ, significantly decreased tumor burden and improved survival. Our findings reveal a previously unknown NRF1-dependent mechanism regulating MM cell survival and present a promising therapeutic approach through the manipulation of its regulatory network.